Slingshot members are tracking this event:

Agios Pharma (AGIO) to report data from Phase 1 study of AG-519 in patients with PK deficiency in at European Hematology Association Meeting

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The purpose of the study is to investigate a drug called AG-519, which is being developed for the treatment of a disease called pyruvate kinase deficiency (also known as PK deficiency) and other forms of anemia. This study is a 3 part study with Part 1 enrolling healthy volunteers into single ascending dose (SAD) groups, Part 2 enrolling healthy volunteers into multiple ascending dose (MAD) groups and Part 3 enrolling healthy volunteers to investigate how much of the study drug is taken up by the body and how food affects the uptake of a prototype formulation of AG-519.
Additional Relevant Details  Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers: 

 - Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -- Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation -
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Interim Data, Phase 1 Data, Ag-519, Pyruvate Kinase Deficiency, Pk Deficiency, European Hematology Association, Double Blind